Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UEJ
|
|||
| Former ID |
DIB000423
|
|||
| Drug Name |
Empagli ozin
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Investigative | [1] | |
| Company |
Boehringer ingelheim pharmaceuticals; eli lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Modulator | [1] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.